In 2015 four new agents were approved for the treatment of multiple myeloma (MM) in the salvage setting, equipping oncology health professionals with more therapeutic options than ever before. But for oncology nurses, this progress also brings the challenge of managing new treatment-related toxicities. Through the use of iPad-based–learning elements, this interactive symposium will provide current information that will help oncology nurses maximize treatment outcomes for patients with relapsed/refractory MM.
Support for this activity has been provided through educational grants from Amgen, Bristol-Myers Squibb, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
